These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 23532890)

  • 1. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET.
    Basilico C; Pennacchietti S; Vigna E; Chiriaco C; Arena S; Bardelli A; Valdembri D; Serini G; Michieli P
    Clin Cancer Res; 2013 May; 19(9):2381-92. PubMed ID: 23532890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
    J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
    Katayama R; Aoyama A; Yamori T; Qi J; Oh-hara T; Song Y; Engelman JA; Fujita N
    Cancer Res; 2013 May; 73(10):3087-96. PubMed ID: 23598276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--response.
    Michieli P; Basilico C; Pennacchietti S
    Clin Cancer Res; 2013 Aug; 19(15):4291. PubMed ID: 23766360
    [No Abstract]   [Full Text] [Related]  

  • 5. Tivantinib (ARQ197) displays cytotoxic activity that is independent of its ability to bind MET--letter.
    Rimassa L; Bruix J; Broggini M; Santoro A
    Clin Cancer Res; 2013 Aug; 19(15):4290. PubMed ID: 23766362
    [No Abstract]   [Full Text] [Related]  

  • 6. Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance.
    Aoyama A; Katayama R; Oh-Hara T; Sato S; Okuno Y; Fujita N
    Mol Cancer Ther; 2014 Dec; 13(12):2978-90. PubMed ID: 25313010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.
    Wei K; Li M; Zöller M; Wang M; Mehrabi A; Hoffmann K
    Cell Death Dis; 2019 Mar; 10(3):231. PubMed ID: 30850583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
    Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines.
    Calles A; Kwiatkowski N; Cammarata BK; Ercan D; Gray NS; Jänne PA
    Mol Oncol; 2015 Jan; 9(1):260-9. PubMed ID: 25226813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes?
    Michieli P; Di Nicolantonio F
    Nat Rev Clin Oncol; 2013 Jul; 10(7):372-4. PubMed ID: 23712183
    [No Abstract]   [Full Text] [Related]  

  • 11. Tivantinib (ARQ-197) exhibits anti-tumor activity with down-regulation of FAK in oral squamous cell carcinoma.
    Xi WH; Yang LY; Cao ZY; Qian Y
    Biochem Biophys Res Commun; 2015 Feb; 457(4):723-9. PubMed ID: 25623532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tivantinib: critical review with a focus on hepatocellular carcinoma.
    Rota Caremoli E; Labianca R
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic activity of the c-Met and tubulin inhibitor tivantinib (ARQ197) with pemetrexed in mesothelioma cells.
    Leon LG; Gemelli M; Sciarrillo R; Avan A; Funel N; Giovannetti E
    Curr Drug Targets; 2014; 15(14):1331-40. PubMed ID: 25483224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification.
    Kim BJ; Kim YJ; Sohn SH; Kim B; Sul HJ; Kim HS; Zang DY
    Invest New Drugs; 2020 Dec; 38(6):1633-1640. PubMed ID: 32361789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1.
    Lu S; Török HP; Gallmeier E; Kolligs FT; Rizzani A; Arena S; Göke B; Gerbes AL; De Toni EN
    Oncotarget; 2015 Sep; 6(26):22167-78. PubMed ID: 26259250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
    Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
    Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for 'Off-Target' Effects Not Mediated by c-Met Inhibition.
    Reuther C; Heinzle V; Spampatti M; Vlotides G; de Toni E; Spöttl G; Maurer J; Nölting S; Göke B; Auernhammer CJ
    Neuroendocrinology; 2016; 103(3-4):383-401. PubMed ID: 26338447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tivantinib in hepatocellular carcinoma.
    Trojan J; Zeuzem S
    Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tivantinib Decreases Hepatocyte Growth Factor-Induced BCRP Expression in Hepatocellular Carcinoma HepG2 Cells.
    Kobayashi K; Higai K; Mukozu T; Matsui D; Amanuma M; Yoshimine N; Ogino Y; Matsui T; Wakui N; Shinohara M; Momiyama K; Daido Y; Nagai H; Igarashi Y
    Biol Pharm Bull; 2020; 43(9):1421-1425. PubMed ID: 32879217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tivantinib (ARQ197) in hepatocellular carcinoma.
    Porta C; Giglione P; Ferrari A; Reversi F; Liguigli W; Imarisio I; Ganini C
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):615-22. PubMed ID: 26035719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.